Wplyw skojarzonego dzialania metycyliny i teikoplaniny na szczepy Staphylococcus aureus w badaniach in vitro

• Autorzy: Mlynarczyk A. , Mlynarczyk G. , Luczak M.

Warianty tytułu

EN

The combination effect of methicillin and teicoplanin against Staphylococcus aureus strains investigated in vitro

• Języki publikacji: PL

Abstrakty

PL

W ostatnich latach wankomycyna i teikoplanina są bardzo często stosowane, a niejednokrotnie nawet nadużywane w leczeniu przeciwbakteryjnym chorych hospitalizowanych. Są lekami z wyboru zarówno w leczeniu zakażeń spowodowanych przez metycylino-oporne szczepy Staphylococcus aureus (MRSA), jak i zakażeń gronkowcami koagulazo-ujemnymi.

EN

The synergy or antagonism between teicoplanin and methicillin against the methicillin-resistant strains of Staphylococcus aureus with decreased susceptibility to vancomycin was studied using agar dilution and E-tests. The investigated strains were GISA and h-GISA isolated in our laboratory as well as standard. In the used range of concentrations, a synergy was shown in the case of two strains and an antagonism was shown in the case of other two strains. For the most strains the tested combination of antibiotics showed indifference. The antagonistic effect was observed in the case of the standard strain Mu3 and the one from eight strains h-GISA isolated in our laboratory.

Słowa kluczowe

PL

infekcja bakteryjna; choroby czlowieka; leczenie; antybiotyki glikopeptydowe; antybiotyki beta-laktamowe; dzialanie skojarzone; antagonizm; badania in vitro; teikoplanina; metycylina; szczepy bakteryjne; Staphylococcus aureus

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2005
• Tom: 57
• Numer: 1
• Opis fizyczny: s.1-6,tab.,bibliogr.

Twórcy

autor

Mlynarczyk A.

• Akademia Medyczna w Warszawie, ul.Chalubinskiego 5, 02-004 Warszawa

autor

Mlynarczyk G.

autor

Luczak M.

Bibliografia

• 1. Bergeret M, Raymond J. In-vitro bactericidal activity of cefpirome and cefamandole in combination with glycopeptides agains methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1999; 43: 219-29.
• 2. Boyle-Vavra S, Yin S, Challapalli M, Daum RS. Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin. Antimicrob Agents Chemother 2003; 47: 1028-36.
• 3. Centers for Disease Control and Prevention. 2004. Vancomycin-resistant Staphylococcus aureus - New York, 2004. Morb Mortal Wkly Rep 2004; 53: 322-3.
• 4. CuiL, Ma X, Sato K i inni. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus J Clin Microbiol 2003; 41: 5-14.
• 5. Hanaki H, Hiramatsu K. Combination effect of teicoplanin and various antibiotics against hetero VRSA and VRSA. Kansenshogaku Zassi, 1999; 73: 1048-53.
• 6. Hanaki H, Yamaguchi Y, Barata K, i inni. Improved method of detection of beta-lactam antibioticinduced VCM-resistant MRSA(BIVR). Int. J Antimicrob Agents, 2004; 23: 311-3.
• 7. Hiramatsu, K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2002; 1:147-55.
• 8. Jones RN, Marshall SA, Grimm H. Antimicrobial Interactions (Synergy) of Teicoplanin with two broad-spectrum drugs (cefotaxime, ofloxacin) tested against Gram-positive isolates from Germany and United States. Diagn Microbiol Infect Dis 1997; 29: 87-94.
• 9. Kim YS, Kim S, Yun HJ, i inni. Efficacy of vancomycin-beta-lactam combinations against heterogeneously vancomycin-resistant Staphylococcus aureus (hetero-VRSA). J Korean Med Sci 2003; 18: 319-24.
• 10. Kim MN, Pai CH, Woo JH i inni. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000; 38: 3879-91.
• 11. Krzyszton-Russjan J, Gniadków ski M] Polowniak-Pracka H i inni. The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland. J Antimicrob Chemother 2002; 50: 1065-9.
• 12. Lozniewski A, Lion C, Mory F, Weber M. In vitro synergy between cefepime and vancomycin against methicillin-susceptible and - resistant Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob. Chemother., 2001; 47: 83-6.
• 13. Marchese A, Balistreri G, Tonoli E i inni. Heterogeneous vancomycin resistance in methicillin- resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol 2000; 38: 866-9.
• 14. Młynarczyk G, Młynarczyk A, Łuczak M. VISA i hetero-VISA wśród szczepów Staphylococcus aureus izolowanych z przypadków klinicznych. Med Dośw Mikrobiol 2002; 54: 9-20.
• 15. Młynarczyk G, Młynarczyk A, Łuczak M. Wpływ antybiotyków beta-laktamowych na poziom wrażliwości na glikopeptydy u Staphylococcus aureus. Med Dośw Mikrobiol 2001, 53(4): 301-9.
• 16. Oliveira GA, Dell'Aquila AM, Masiero RL i inni. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect Control Hosp Epidemiol. 2001 ; 22:443-8.
• 17. Otsuka Y, Shimamura Y Yoshibe T, Ezaki T. Successful combination therapy of teicoplanin with cefmetazole on postoperative cardiovascular MRSA infections: clinical report on two cases. .Tpn JAntibiot 2003; 56: 55-60.
• 18. Ploy MC, Grelaud C, Martin C i inni. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.